{"id":8125,"date":"2025-07-27T08:54:58","date_gmt":"2025-07-27T05:54:58","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8125"},"modified":"2025-07-27T08:54:58","modified_gmt":"2025-07-27T05:54:58","slug":"polypills-could-prevent-up-to-72-million-heart-disease-deaths","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/polypills-could-prevent-up-to-72-million-heart-disease-deaths\/","title":{"rendered":"Polypills Could Prevent Up to 72 Million Heart Disease Deaths"},"content":{"rendered":"<div>Polypills Could Prevent Up to 72 Million Heart Disease Deaths<\/div>\n<div><\/div>\n<div>Source:<\/div>\n<div>Highlighted on: July 22, 2025<\/div>\n<div>Published in: JACC, 14 July 2025<\/div>\n<div><\/div>\n<div>Key Findings:<\/div>\n<div><span> 1. What are polypills?<\/span><\/div>\n<div>A polypill is a single pill that combines several heart-protecting medications such as:<\/div>\n<div><span> \u2022 A statin (for cholesterol)<\/span><\/div>\n<div><span> \u2022 One or more blood pressure drugs<\/span><\/div>\n<div><span> \u2022 Sometimes aspirin (to prevent clotting)<\/span><\/div>\n<div><span> 2. Why are they important?<\/span><\/div>\n<div>Many people at high risk of heart disease do not get the proper medications\u2014even in wealthy countries. Polypills could make treatment easier and more accessible.<\/div>\n<div><span> 3. What did the researchers study?<\/span><\/div>\n<div>Scientists modeled how giving polypills from 2023 to 2050 could impact heart disease globally. They looked at heart attack, stroke, heart failure, and deaths from cardiovas\u2026<\/div>\n<div>[4:04 pm, 25\/07\/2025] Dr Jamal Aldabbas Card Socity: Interest rising in CKM syndrome as connections become clearer<\/div>\n<div>Date: Highlighted on 24 July 2025<\/div>\n<div>In AHA articles on CKM syndrome and the PREVENT calculator.<\/div>\n<div><\/div>\n<div>1.<span> <\/span>What is CKM Syndrome?<\/div>\n<div><span> \u2022 CKM stands for Cardiovascular-Kidney-Metabolic syndrome.<\/span><\/div>\n<div><span> \u2022 It is a progressive condition now officially recognized by the American Heart Association (AHA).<\/span><\/div>\n<div><span> \u2022 It links heart disease, kidney disease, and metabolic disorders (like diabetes and obesity) into one unified risk spectrum.<\/span><\/div>\n<div><span> 2. Disease Staging (According to the 2023 AHA Statement):<\/span><\/div>\n<div><span> \u2022 Stage 1: Excess body fat, especially abdominal.<\/span><\/div>\n<div><span> \u2022 Stage 2: Development of metabolic diseases (diabetes, hypertension, CKD).<\/span><\/div>\n<div><span> \u2022 Stage 3: Subclinical cardiovascular disease (visible on imaging but without symptoms).<\/span><\/div>\n<div><span> \u2022 Stage 4: Full cardiovascular events (heart attack, stroke, PAD, heart failure).<\/span><\/div>\n<div><span> 3. New Tool \u2013 PREVENT Calculator:<\/span><\/div>\n<div><span> \u2022 Introduced by the AHA to help predict CKM progression.<\/span><\/div>\n<div><span> \u2022 Uses lab values (HbA1C, urine albumin-to-creatinine ratio) and social determinants of health.<\/span><\/div>\n<div><span> 4. Clinical Implications:<\/span><\/div>\n<div><span> \u2022 Cardiologists may see CKM patients before nephrologists or endocrinologists.<\/span><\/div>\n<div><span> \u2022 This highlights the need for interdisciplinary care and early risk detection.<\/span><\/div>\n<div><span> 5. Recent Studies (2024 AHA Scientific Sessions):<\/span><\/div>\n<div><span> \u2022 Tighter BP control (targeting 120 mmHg) in diabetics reduces CV events.<\/span><\/div>\n<div><span> \u2022 Tirzepatide, a GIP\/GLP-1 agonist, improves outcomes in HFpEF patients.<\/span><\/div>\n<div><span> 6. Gender Disparities:<\/span><\/div>\n<div><span> \u2022 Women with CKM syndrome have 38% higher mortality risk than men.<\/span><\/div>\n<div><span> \u2022 Prevention and treatment must be more aggressive and tailored in women.<\/span><\/div>\n<div><span> 7. CKM as a Global Challenge:<\/span><\/div>\n<div><span> \u2022 ~90% of the U.S. population is already at stage 1 or higher.<\/span><\/div>\n<div><span> \u2022 About 50% are in stage 2.<\/span><\/div>\n<div><span> \u2022 The worldwide burden is possibly in the billions.<\/span><\/div>\n<div><span> 8. Future of Care \u2013 Cardiometabolic Clinics:<\/span><\/div>\n<div><span> \u2022 A growing model where cardiologists, endocrinologists, and nephrologists work together.<\/span><\/div>\n<div><span> \u2022 More specialists will be trained in cardiometabolic medicine.<\/span><\/div>\n<div><span> 9. Call to Action for Cardiologists:<\/span><\/div>\n<div><span> \u2022 Start screening for early CKD (UACR) and HbA1C.<\/span><\/div>\n<div><span> \u2022 Consider SGLT2 inhibitors and GLP-1 agonists for prevention.<\/span><\/div>\n<div><span> \u2022 Shift toward preventive and personalized care is essential.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/professional.heart.org\/en\/guidelines-and-statements\/prevent-calculator\">https:\/\/professional.heart.org\/en\/guidelines-and-statements\/prevent-calculator<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Polypills Could Prevent Up to 72 Million Heart Disease Deaths Source: Highlighted on: July 22, 2025 Published in: JACC, 14 July 2025 Key Findings: 1. What are polypills? A polypill is a single pill that combines several heart-protecting medications such as: \u2022 A statin (for cholesterol) \u2022 One or more blood pressure drugs \u2022 Sometimes [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8125","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8125"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8125\/revisions"}],"predecessor-version":[{"id":8126,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8125\/revisions\/8126"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}